Cohance Lifesciences Limited has informed the Exchange about General Updates
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences has received an order dated July 18, 2025 from the Reserve Bank of India (Foreign Exchange Department, Mumbai) approving the compounding of an alleged violation of the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019. The issue relates to foreign investments made in ZCL Chemicals Limited in 2021, which later merged with Erstwhile Cohance in February 2024 and then with the Company in May 2025. A compounding fee of Rs. 8.30 crore (Rs. 8,29,88,900) is payable to the RBI within 15 days. The Department of Pharmaceuticals had already granted a post-facto approval in 2022. The fee was already fully provisioned in the financial statements of Erstwhile Cohance for the year ended March 31, 2025.
Minimal impact on shareholders — the ~Rs. 8.30 crore compounding fee is already accounted for in the books, and the company confirms no other financial, operational, or material impact. The order effectively closes a legacy compliance matter inherited from a predecessor entity.